Good
Mostly Aligned
Patient Risk:
Low
Summary
Most AI claims match label-supported indications, mechanism/clinical effects, and common adverse reactions for amlodipine. Minor precision gaps exist around “common” frequency language and rescue/attack-stopping claims, which are not explicitly addressed in the provided label excerpts.
Category Scores
Accurate Statements
Amlodipine tablets are used to treat high blood pressure (hypertension).
Section 1 Indications: “Amlodipine is indicated for the treatment of hypertension.”
Amlodipine tablets are used to help prevent certain types of chest pain (angina).
Section 1 Indications: symptomatic treatment of chronic stable angina; vasospastic angina indications.
Amlodipine is a calcium channel blocker.
Section 12 Clinical Pharmacology: dihydropyridine calcium antagonist; inhibits calcium influx into smooth muscle/cardiac muscle.
Amlodipine relaxes blood vessels.
Section 12: peripheral arterial vasodilator causing reduction in peripheral vascular resistance and reduction in blood pressure.
Amlodipine lowers blood pressure.
Section 12: reduction in blood pressure.
Amlodipine reduces how hard the heart has to work.
Consistent with Section 12/clinical studies describing reduced peripheral resistance and antianginal effects; however no direct label phrasing matching this exact wording is provided in excerpts.
Amlodipine helps prevent angina episodes.
Section 14 clinical studies: decreases angina attack rate (chronic stable angina) and decreased attacks (vasospastic angina).
Amlodipine helps prevent angina caused by reduced blood flow to the heart.
Supported indirectly by chronic stable angina indication and Section 14 describing reductions in angina attack rate; label excerpt does not explicitly use the phrase “reduced blood flow.”
Amlodipine helps decrease the frequency of chest pain in people with chronic stable angina.
Section 14: amlodipine decreased angina attack rate; effectiveness of 5 to 10 mg/day for chronic stable angina.
Amlodipine is taken regularly as prescribed to control blood pressure.
Section 2 Dosage/Administration: once-daily oral dosing regimen for hypertension.
Amlodipine is taken regularly as prescribed to help prevent angina.
Section 2 Dosage/Administration: recommended dose range for chronic stable or vasospastic angina (5–10 mg) and Section 14 shows attack reductions with therapy.
People taking amlodipine commonly report swelling in the legs or ankles (edema).
Section 6: “Most common side effects are headache and edema.”
People taking amlodipine commonly report headache.
Section 6: “Most common side effects are headache and edema.”
Unsupported Statements
Amlodipine is not typically used as a 'rescue' medicine to stop an angina attack once it starts.
The provided label excerpts include no explicit statement about not using amlodipine as a rescue/acute-attack medication.
People taking amlodipine commonly report dizziness.
The provided label excerpts list headache and edema as most common, but do not state dizziness as a common adverse reaction.
People taking amlodipine commonly report flushing.
The provided label excerpts do not state flushing as a common adverse reaction.
People taking amlodipine commonly report fatigue.
The provided label excerpts do not state fatigue as a common adverse reaction.
Amlodipine reduces how hard the heart has to work.
No direct label excerpt uses this phrasing; the antianginal effect is supported, but the exact “how hard the heart has to work” wording is not explicitly supported in the provided text.
Amlodipine helps prevent angina caused by reduced blood flow to the heart.
The label excerpt supports chronic stable angina and attack reductions, but does not explicitly describe the cause as “reduced blood flow.”
Contradictions
Important Omissions
The label excerpt provided does not mention a boxed warning; if the AI response claimed none, that claim is not assessable here. (No explicit boxed-warning claim was provided to evaluate.)
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Unverified safety/AE frequency statements (dizziness/flushing/fatigue as “commonly report”) could mislead on expected side effects. The rest of the claims largely align with on-label indications and general clinical effects.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several adverse reaction claims are labeled as “commonly” without support in the provided excerpts (dizziness, flushing, fatigue), and the 'rescue' use statement is not addressed in the excerpts.
Suggested Improvement
Limit AE frequency claims to those explicitly labeled as most common (headache, edema) from Section 6; remove or qualify statements about “rescue” use unless the label excerpts explicitly address this.